Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator

Claude Manelfe, Vincent Larrue, Rüdiger Von Kummer, Luigi Bozzao, Peter Ringleb, Stefano Bastianello, Françoise Iweins, Emmanuel Lesaffre

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Background and Purpose-The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. Methods-Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. Results-We found an HMCAS in 107 patients(17.7%). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P

Original languageEnglish
Pages (from-to)769-772
Number of pages4
JournalStroke
Volume30
Issue number4
Publication statusPublished - Apr 1999

Fingerprint

Middle Cerebral Artery
Tissue Plasminogen Activator
Stroke
Multicenter Studies
Thrombosis
Placebos

Keywords

  • Stroke assessment
  • Stroke outcome
  • Stroke, acute
  • Thrombolytic therapy
  • Tomography, x-ray computed

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Manelfe, C., Larrue, V., Von Kummer, R., Bozzao, L., Ringleb, P., Bastianello, S., ... Lesaffre, E. (1999). Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke, 30(4), 769-772.

Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. / Manelfe, Claude; Larrue, Vincent; Von Kummer, Rüdiger; Bozzao, Luigi; Ringleb, Peter; Bastianello, Stefano; Iweins, Françoise; Lesaffre, Emmanuel.

In: Stroke, Vol. 30, No. 4, 04.1999, p. 769-772.

Research output: Contribution to journalArticle

Manelfe, C, Larrue, V, Von Kummer, R, Bozzao, L, Ringleb, P, Bastianello, S, Iweins, F & Lesaffre, E 1999, 'Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator', Stroke, vol. 30, no. 4, pp. 769-772.
Manelfe, Claude ; Larrue, Vincent ; Von Kummer, Rüdiger ; Bozzao, Luigi ; Ringleb, Peter ; Bastianello, Stefano ; Iweins, Françoise ; Lesaffre, Emmanuel. / Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. In: Stroke. 1999 ; Vol. 30, No. 4. pp. 769-772.
@article{29e6410ee29245abbc8399dbfabbd920,
title = "Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator",
abstract = "Background and Purpose-The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. Methods-Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. Results-We found an HMCAS in 107 patients(17.7{\%}). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P",
keywords = "Stroke assessment, Stroke outcome, Stroke, acute, Thrombolytic therapy, Tomography, x-ray computed",
author = "Claude Manelfe and Vincent Larrue and {Von Kummer}, R{\"u}diger and Luigi Bozzao and Peter Ringleb and Stefano Bastianello and Fran{\cc}oise Iweins and Emmanuel Lesaffre",
year = "1999",
month = "4",
language = "English",
volume = "30",
pages = "769--772",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator

AU - Manelfe, Claude

AU - Larrue, Vincent

AU - Von Kummer, Rüdiger

AU - Bozzao, Luigi

AU - Ringleb, Peter

AU - Bastianello, Stefano

AU - Iweins, Françoise

AU - Lesaffre, Emmanuel

PY - 1999/4

Y1 - 1999/4

N2 - Background and Purpose-The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. Methods-Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. Results-We found an HMCAS in 107 patients(17.7%). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P

AB - Background and Purpose-The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. Methods-Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. Results-We found an HMCAS in 107 patients(17.7%). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P

KW - Stroke assessment

KW - Stroke outcome

KW - Stroke, acute

KW - Thrombolytic therapy

KW - Tomography, x-ray computed

UR - http://www.scopus.com/inward/record.url?scp=0032892454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032892454&partnerID=8YFLogxK

M3 - Article

C2 - 10187877

AN - SCOPUS:0032892454

VL - 30

SP - 769

EP - 772

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 4

ER -